96 patents
Utility
Bromodomain Inhibitors for Androgen Receptor-driven Cancers
18 Jan 24
Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed.
Sylvie GUICHARD, Maureen CALIGIURI, Anna ERICSSON, Qunli XU, Hesham MOHAMED
Filed: 22 Sep 23
Utility
Treating Sickle Cell Disease with a Pyruvate Kinase R Activating Compound
30 Nov 23
Compounds that activate pyruvate kinase R can be used for the treatment of sickle cell disease (SCD).
Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, Bingsong HAN, David R. Lancia, JR., Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN, Chase C. SMITH, Zhongguo WANG, Xiaozhang ZHENG
Filed: 22 Dec 22
Utility
Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors
14 Nov 23
The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.
Alex J. Buckmelter, Justin Andrew Caravella, Hongbin Li, Matthew W. Martin, Steven Mischke, David James Richard, Angela V. West
Filed: 20 Oct 22
Utility
Bromodomain inhibitors for androgen receptor-driven cancers
31 Oct 23
Methods for treating certain androgen receptor-positive forms of cancer using inhibitors of the CREB binding protein bromodomain are disclosed.
Sylvie Guichard, Maureen Caligiuri, Anna Ericsson, Qunli Xu, Hesham Mohamed
Filed: 23 Sep 21
Utility
Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
24 Oct 23
The present disclosure is directed to solid and salt forms of inhibitors of the CBP/p300 family of bromodomains made up of salts and crystalline forms of Formula (I).
George Luke, Suresh Babu
Filed: 23 Sep 21
Utility
Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors
17 Oct 23
The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains.
Shawn E. R. Schiller, Torsten Herbertz, Hongbin Li, Bradford Graves, Steven Mischke, Angela V. West, Jennifer R. Downing, Anna Ericsson
Filed: 10 Feb 22
Utility
Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
15 Aug 23
The present disclosure reports solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile.
George P. Luke, Pratik Sheth
Filed: 24 Feb 21
Utility
Composite Conduit Formwork Structure and Method of Fabrication
29 Jun 23
The disclosure presents a composite conduit formwork structure which includes a cylindrical outer casing adapted to bond with a cylindrical inner casing which are maintained at a fixed distance apart by a plurality of radial stanchions.
Scott Armstrong
Filed: 27 Feb 23
Utility
Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
16 May 23
The disclosure relates to modulating pyruvate kinase and provides novel chemical compounds useful as activators of PKR, as well as various uses of these compounds.
Anna Ericsson, Neal Green, Gary Gustafson, Bingsong Han, David R. Lancia, Jr., Lorna Mitchell, David Richard, Tatiana Shelekhin, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
Filed: 23 Apr 21
Utility
PYRIDIN-2(1H)-ONE Quinolinone Derivatives As Mutant-isocitrate Dehydrogenase Inhibitors
27 Apr 23
Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, JR., Justin Andrew Caravella, Wei Lu
Filed: 9 Nov 22
Utility
Fused Pyrrolines Which Act As Ubiquitin-specific Protease 30 (USP30) Inhibitors
27 Apr 23
The disclosure relates to USP30 Inhibitor Compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and medical uses involving same.
Alex J. Buckmelter, Justin Andrew Caravella, Hongbin Li, Matthew W. Martin, Steven Mischke, David James Richard, Angela V. West
Filed: 20 Oct 22
Utility
Treating Patients Harboring an Isocitrate DEHYDROGENASE-1 (IDH-1) Mutation
30 Mar 23
Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 14 Nov 22
Utility
Tetrahydroquinoline Compositions As Bet Bromodomain Inhibitors
2 Mar 23
Kenneth W. Bair, Torsten Herbertz, Goss S. Kauffman, Katherine J. Kayser-Bricker, George P. Luke, Matthew W. Martin, David S. Millan, Shawn E.R. Schiller, Adam C. Talbot
Filed: 23 Jul 21
Utility
Inhibiting Ubiquitin Specific Peptidase 9X
2 Mar 23
The disclosure provides novel chemical compounds useful as inhibitors of ubiquitin specific peptidase 9X (USP9X).
Bruce FOLLOWS, Katherine J. KAYSER-BRICKER, Adam Charles TALBOT, Scot MENTE, Tatiana SHELEKHIN, Anna ERICSSON
Filed: 19 Sep 19
Utility
INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
2 Mar 23
Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
Patrick F. Kelly, Susan Ashwell, Blythe Thomson, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
Filed: 21 Mar 22
Utility
Composite conduit formwork structure and method of fabrication
28 Feb 23
The disclosure presents a composite conduit formwork structure which includes a cylindrical outer casing adapted to bond with a cylindrical inner casing which are maintained at a fixed distance apart by a plurality of radial stanchions.
Scott Armstrong
Filed: 10 Nov 20
Utility
Activating Pyruvate Kinase R
23 Feb 23
The disclosure provides novel chemical compounds useful as activators of PKR.
Xiaozhang ZHENG, Anna ERICSSON, Neal GREEN, Gary GUSTAFSON, David R. LANCIA, Jr., Jian LIN, Lorna MITCHELL, David RICHARD, Tatiana SHELEKHIN
Filed: 19 Sep 19
Utility
Inhibiting mutant IDH-1
14 Feb 23
Methods of treating patients diagnosed with cancer harboring an IDH-1 mutation are provided, including the therapeutic administration of a certain inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA).
Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Susan Ashwell, Blythe Thomson, Wei Lu
Filed: 16 May 19
Utility
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
31 Jan 23
This disclosure relates to compositions and methods for inhibiting mutant IDH1, useful in treatment of mIDH1 cancers including AML, as well as mIDH1-positive solid tumors such as glioma.
Jian Lin, George P. Luke, Madhu Mondal
Filed: 19 Nov 20
Utility
Reconfigurable composite floor formwork and method of use
3 Jan 23
The disclosure presents a reconfigurable composite floor formwork which defined by a plurality of interlocking fiberglass panels formed into profiles which may be moved and adapted to provide a concrete form for a floor or ceiling.
Scott Armstrong
Filed: 10 Nov 20